Filing Details

Accession Number:
Form Type:
Zero Holdings:
Publication Time:
2021-01-20 20:20:13
Reporting Period:
Accepted Time:
2021-01-20 20:20:13
SEC Url:
Form 4 Filing
Cik Name Symbol Sector (SIC) IRS No
1377121 Protagonist Therapeutics Inc PTGX () DE
Cik Name Reported Address Insider Title Director Officer Large Shareholder Other
1120477 D Ph V Dinesh Patel C/o Protagonist Therapeutics, Inc.
7707 Gateway Blvd., Suite 140
Newark CA 94560
President And Ceo Yes Yes No No
Reported Non-Derivative Transactions
Sec. Name Acquisiton - Disposition Date Amount Price Remaning Holdings Equity Swap Involved Form Type Code Nature of Ownership Explanation
Common Stock Acquisiton 2021-01-19 13,000 $4.21 450,990 No 4 M Direct
Common Stock Disposition 2021-01-19 24,846 $24.60 426,144 No 4 S Direct
Equity Swap Involved Form Type Code Nature of Ownership Explanation
No 4 M Direct
No 4 S Direct
Reported Derivative Transactions
Sec. Name Sec. Type Acquisiton - Disposition Date Amount Price Amount - 2 Price - 2
Common Stock Stock Option (right to buy) Disposition 2021-01-19 13,000 $0.00 13,000 $4.21
Remaning Holdings Exercise Date Expiration Date Equity Swap Involved Transaction Form Type Transaction Code Nature of Ownership
165,742 2026-04-29 No 4 M Direct
  1. The sales reported in this Form 4 include: (a) the open market sale of 13,000 shares of common stock acquired pursuant to the exercise of options to purchase common stock; and (b) the open market sale of an additional 11,846 shares of common stock. Such transactions were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 6, 2020.
  2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.01 to $24.95, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
  3. 1/48th of the shares subject to the option vested on the last day of each month following the vesting commencement date. The option became fully vested on April 25, 2020.